Loss of heterozygosity on chromosome 16q increases relapse risk in Wilms’ tumor: a meta-analysis
PDF | HTML | How to cite
Metrics: PDF 1106 views | HTML 2007 views | ?
Zhenyu Pan1,2,*, Hairong He1,*, Lina Tang3, Qingting Bu4, Hua Cheng2, Anmin Wang2, Jun Lyu1 and Haisheng You3
1Clinical Research Center, The First Affiliated Hospital of Xi'an Jiaotong University, Xi’an, Shaanxi, 710061, China
2Department of Pharmacy, Xi’an Jiaotong University Affiliated Children’s Hospital, Xi’an, Shaanxi, 710003, China
3Department of Pharmacy, The First Affiliated Hospital of Xi'an Jiaotong University, Xi’an, Shaanxi, 710061, China
4Department of Genetics, Northwest Women’s and Children’s Hospital, Xi’an, Shaanxi, 710061, China
*Authors contributed equally to this work
Haisheng You, email: [email protected]
Jun Lyu, email: [email protected]
Keywords: Wilms’ tumor, LOH 16q, relapse, meta-analysis
Received: June 28, 2017 Accepted: August 06, 2017 Published: August 11, 2017
Wilms’ tumor (WT) is the most frequent malignant renal tumor in children. The survival rate is lower in patients with recurrence, and the factors that influence relapse in WT are not fully understood. Loss of heterozygosity on chromosome 16q (LOH 16q) has been reported to be associated with the relapse in WT, but this remains controversial. We performed a meta-analysis to clarify this. PUBMED, EMBASE, and the Cochrane Library were searched up to March 17, 2017. Ten studies involving 3385 patients were ultimately included in the meta-analysis. The meta-analysis showed that LOH 16q was significantly associated with the relapse in WT (relative risk [RR] = 1.74, 95% confidence interval [CI] = 1.43–2.13, P < 0.00001; hazard ratio [HR] = 1.76, 95% CI = 1.38–2.24, P < 0.00001). No significant heterogeneity among studies or publication bias was found. Sensitivity analysis showed omitting one study in each turn could not change the results. Subgroup analysis based on two studies indicated LOH 16q was more effective on elevated replase risk in patients with favorable-histology WT (RR = 2.52, 95% CI = 1.68–3.78, P < 0.00001; HR = 2.99, 95% CI = 1.84–4.88, P < 0.0001) but further work are needed to confirm this. These findings confirm that LOH 16q increased the relapse risk in WT, but more studies are required to further assess the association between LOH 16q and WT relapse among different subgroups.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.